Form 4: Bicara Therapeutics Director Jake Simson Granted Stock Options Under 2024 Incentive Plan

Bicara Therapeutics Inc. director Jake Simson was granted 23,746 stock options with an exercise price of $11.48, vesting upon the earlier of June 9, 2026, or the next Annual Meeting, though he disclaims beneficial ownership due to an arrangement with RA Capital Management.

Summary

• Director Jake Simson of Bicara Therapeutics Inc. (BCAX) was granted 23,746 stock options.
• The options have an exercise price of $11.48 per share.
• The grant was made on June 9, 2025, under the Issuer's 2024 Stock Option and Incentive Plan.
• The shares underlying this option will vest upon the earlier of June 9, 2026, or the date of the next Annual Meeting of Stockholders, contingent on Mr. Simson's continued service.
• The option expires on June 9, 2035.
• Mr. Simson holds this option for the benefit of R.A. Capital Healthcare Fund, L.P. and R.A. Capital Nexus Fund III, L.P., and is obligated to turn over any net proceeds to RA Capital Management, L.P. to offset advisory fees.
• Consequently, Mr. Simson disclaims beneficial ownership of the option and the underlying common stock.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is generally a positive sign of alignment and incentive. However, the disclaimer of beneficial ownership by the director due to the arrangement with RA Capital Management introduces a neutral element, as the direct personal financial incentive for the individual is mitigated.

Positives

• The grant of stock options to a director aligns their interests with shareholders, providing an incentive for long-term performance.
• The option grant is part of the company's 2024 Stock Option and Incentive Plan, indicating a structured approach to executive compensation and retention.

Negatives

• The reporting person, Jake Simson, disclaims beneficial ownership of the options and underlying common stock, as they are held for the benefit of RA Capital Management funds, meaning he does not personally benefit from the appreciation of these specific shares.

Future Outlook

The stock options granted to Director Jake Simson are set to vest upon the earlier of June 9, 2026, or the date of the next Annual Meeting of Stockholders, subject to his continued service, providing a future incentive tied to company performance.

Industry Context

This Form 4 filing is a routine disclosure of an equity grant to a director, common practice in the biotechnology and pharmaceutical industry to align executive and board member interests with long-term shareholder value. The involvement of RA Capital Management, a prominent healthcare investment firm, highlights the typical financial structures and relationships within the sector.

Related Party Transactions

• The reporting person, Jake Simson, holds the stock option for the benefit of R.A. Capital Healthcare Fund, L.P. and R.A. Capital Nexus Fund III, L.P.
• He is obligated to turn over any net cash or stock received upon exercise to RA Capital Management, L.P. to offset advisory fees owed by the aforementioned funds. This arrangement constitutes a related party transaction as Mr. Simson is a director and likely associated with RA Capital Management.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with long-term shareholder value, though the specific arrangement means the director's personal financial gain from these options is indirect.
• RA Capital Management Funds: These funds are the ultimate beneficiaries of the option's value, as proceeds will offset their advisory fees.

Next Steps

• The stock options will vest upon the earlier of June 9, 2026, or the date of the next Annual Meeting of Stockholders, contingent on Jake Simson's continued service.
• Upon exercise, any net cash or stock received will be turned over to RA Capital Management, L.P. to offset advisory fees owed by the R.A. Capital Healthcare Fund, L.P. and R.A. Capital Nexus Fund III, L.P.

Key Dates

Keywords

Bicara Therapeutics, BCAX, Form 4, SEC Filing, Stock Option, Director Compensation, Equity Grant, Beneficial Ownership, RA Capital Management, Incentive Plan